Posts by: Joana Carvalho

News

Long-term treatment with Novoeight (turoctocog alfa) is safe and effective at preventing bleeding episodes in patients with hemophilia A of all ages who had already received prior treatment, a Phase ... Read more

January 2, 2019January 11, 2019

Catalyst Announces Updates on Two Lead Compounds for Hemophilia

News

Catalyst Biosciences recently announced updates on two of its lead compounds — Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) and Factor IX (FIX) dalcinonacog alfa (DalcA) — for treatment of hemophilia A or B with inhibitors, and ... Read more

December 19, 2018December 19, 2018

Preventive Use of Idelvion Lets Kids with Hemophilia B Need Fewer Infusions, Trial Shows

News

Prophylaxis with Idelvion (rIX‐FP) significantly improved clinical outcomes and quality of life for children with hemophilia B and eased daily life for their caregivers, Phase 3 clinical trial data ... Read more

November 30, 2018November 30, 2018

Bayer Announces the Approval of Jivi for Hemophilia A in Europe

News

Jivi (BAY94-9027), a lab-made version of the blood clotting factor VIII (FVIII), has been approved by the European Commission for the prophylactic (preventative) treatment of hemophilia A in patients older ... Read more

November 7, 2018November 7, 2018

Bioverativ to Present New Data on Hemophilia and Other Blood Disorders at ASH

News

Bioverativ will present some of its most recent therapeutic advancements regarding hemophilia and other blood diseases at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, ... Read more

September 5, 2018September 5, 2018

Hemlibra Reduces Bleeds in Hemophilia A Patients Without Inhibitors, Phase 3 Trial Shows

News

Hemlibra (emicizumab) was able to prevent excessive bleeding in patients with severe hemophilia A without inhibitors, according to results from a Phase 3 trial. Trial findings were published in the study, ... Read more

Posts by: Joana Carvalho

Joana Carvalho

Novoeight Safe, Effective in Hemophilia A Patients Over Long Term, Phase 3b Trial Shows

Catalyst Announces Updates on Two Lead Compounds for Hemophilia

Preventive Use of Idelvion Lets Kids with Hemophilia B Need Fewer Infusions, Trial Shows

Bayer Announces the Approval of Jivi for Hemophilia A in Europe

Bioverativ to Present New Data on Hemophilia and Other Blood Disorders at ASH

Hemlibra Reduces Bleeds in Hemophilia A Patients Without Inhibitors, Phase 3 Trial Shows

Pin It on Pinterest